M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData

CMOs showed an increasing reluctance to take on debt in 2022

SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue

Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders

Dr Reddys Laboratories signs for consumption of renewable energy

JeNaCell launches wound dressing epicite balance for chronic wounds

Moist wound dressing for chronic wound treatment now available in Germany

Dabur India expects 10%+ consolidated growth in Q1 FY24

However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.

Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries

Solara Active Pharma approves rights issue of Rs. 450 Cr

The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.

ENPICOM secures extended financing from current investors

Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals